Materials and Reagents
Highland barley powder: purchased from Qinghai Hanhe Biotechnology Co., Ltd.
Enzymatic hydrolysis of highland barley powder: laboratory-made. Under the conditions of pullulanase concentration of 200 U/g highland barley powder, α-glucosidase concentration of 80 U/g highland barley powder, enzymatic hydrolysis time of 3 h, enzymatic hydrolysis temperature of 55°C, and Solid-liquid ratio 1:15 g/mL, The content of slow-digestible starch in double-enzyme enzymatic hydrolysis of highland barley flour was 28.01%.
Instruments and equipment
AB Triple TOF 6600 mass spectrometer (AB SCIEX)
Agilent 1290 Infinity LC ultra-high pressure liquid chromatograph (Agilent)
Low temperature high-speed centrifuge (Eppendorf 5430R)
Chromatographic column: Waters, ACQUITY UPLC BEH C-18 1.7 µm, 2.1 mm×100 mm column Acetonitrile (Merck, 1499230-935)
Ammonium acetate (Sigma, 70221)
Methods
Extraction of metabolites
After the samples were slowly thawed at 4°C, an appropriate amount of samples was added to pre-cooled methanol/acetonitrile/water solution (2:2:1, v/v), mixed by vortex, sonicated at low temperature for 30 min, and allowed to stand at -20°C for 10 min. Centrifuge at 14,000 g at 4°C for 20 min, taked the supernatant and dried it in vacuo, added 100 µL of acetonitrile aqueous solution (acetonitrile: water = 1:1, v/v) to reconstitute, vortex, and centrifuge at 14,000 g at 4°C for 15 min. Supernatant injection analysis.
Chromatography-Mass Spectrometry
The samples were separated by an Agilent 1290 Infinity LC ultra-high performance liquid chromatography (UHPLC) C-18 column; the column temperature was 40°C; the flow rate was 0.4 mL/min; the injection volume was 2 µL; mobile phase composition A: water + 25 mM acetic acid Ammonium + 0.5% formic acid, B: methanol; the gradient elution procedure is as follows: 0–0.5 min, 5% B; 0.5–0 min, B linearly changes from 5–100%; 10.0–12.0 min, B maintained at 100%; 12.0–12.1 min, B linearly changed from 100–5%; 12.1–16 min, B maintained at 5%; the sample was placed in an autosampler at 4°C throughout the analysis. In order to avoid the influence caused by the fluctuation of the instrument detection signal, the continuous analysis of the samples is carried out in random order. QC samples are inserted into the sample queue to monitor and evaluate the stability of the system and the reliability of experimental data.
The primary and secondary spectra of the samples were collected using an AB Triple TOF 6600 mass spectrometer. The ESI source conditions after HILIC chromatographic separation are as follows: Ion Source Gas1: 60, Ion Source Gas2: 60, Curtain gas: 30, source temperature: 600℃, IonSapary Voltage Floating ± 5500 V (positive and negative modes); TOF MS scan m/z range: 60–1000 Da, production scan m/z range: 25–1000 Da, TOF MS scan accumulation time 0.20 s/spectra, production scan accumulation time 0.05 s/spectra; MS was acquired with information dependent acquisition (IDA) and used in high sensitivity mode, Declustering potential (DP): ±60 V (both positive and negative modes), Collision Energy: 35 ± 15 eV, IDA setting As follows Exclude isotopes within 4 Da, Candidate ions to monitor per cycle: 10.
Data processing and analysis
For untargeted metabolomics data, raw ms data (wiff. scan files) were converted to mzXML files using proteowizard msconvert, imported into freely available xcms software, and then used for alignment, peak detection and retention time correction. In addition, multivariate statistical analysis, including PCA, PLS-DA, and OPLS-DA, was performed using simca software (version 14.0), and used Heatmaps were drawn, and functional annotation of metabolites and enrichment analysis of metabolic pathways were evaluated using the database of the Kyoto gg Encyclopedia of Genes and Genomes
Untargeted metabolomic analysis
Sample analysis
Similarities and differences of samples were detected by PCA. The data acquisition performance of the equipment was monitored using quality control samples during the analysis. In both anion and cation detection modes, dense clustering of quality control samples shows that the variation caused by instrumental error is small throughout the test, and the test data is reliable. The PG group and the control group were distributed on the left and right sides of the PCA score graph, indicating a separation between the two (Fig. 1a and 2a).
Partial Least Squares Discriminant Analysis (PLS-DA) and Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA)
To optimize the separation between groups, the two groups of samples were further analyzed using PLS-DA and OPLS-DA after removal of the control samples. As shown in Fig. 1b,2b and Fig. 1c,2c, the PG group and the control group exhibited trends of intra-group aggregation and inter-group segregation in both modes, which was more pronounced in OPLS-DA. The results showed that the metabolic pattern of highland barley starch changed under the conditions of enzymatic hydrolysis. In order to avoid overfitting of the supervised model in the modeling process, the permutation test method is used to test the model to ensure the validity of the model. Figure 1d,2d and Fig. 1e,2e,show the PLS-DA (R2X = 0.992, R2Y = 1, q2 = 0.999) and OPLS-DA (R2X = 0.992, R2Y = 1, q2 = 0.999) of the PG group and the Control group in both anionic and cationic ion modes ); permutation test plots of PLS-DA (R2X = 0.953, R2Y = 0.998, q2 = 0.988) and OPLS-DA (R2X = 0.953, R2Y = 0.998, q2 = 0.987). As the replacement retention rate gradually decreased, the R2 and Q2 of the random model gradually decreased, indicating that there was no overfitting in the original model. This indicates that PLS-DA and OPLS-DA showed statistically significant separation of metabolites between groups.
Screening and identification of differential metabolites
Different metabolites with biological significance were found according to the projected variable importance (VIP) obtained by OPLS-DA. As shown in Table 1, in the anion detection mode, 39 differential metabolites were identified by matching with the database (VIP > 1.0, P < 0.05). Among them, 13 differential metabolites were related to the KEGG metabolic pathway, including Lipids and lipid-like molecules (gamma-Linolenic acid), phenylpropanoids and polyketides ((-)-epicatechin, apigenin, epigallocatechin, geranin, procyanidin B2), organic acids and derivatives (L-Pyroglutamic acid, L-Malic acid, Gluconic acid), organic oxygen compounds (D-Glucose, Stachyose, Trehalose, Raffinose). Among these metabolites, 5 metabolites were up-regulated and 34 were down-regulated. The up-regulated metabolites included flavonoids, benzene and substituted derivatives, organic oxygen compounds, etc. Down-regulated metabolites include hydroxyl acids and derivatives, flavonoids, etc.
Table 1
The negative detection mode (opls-da vip > 1, p value < 0.05), the differential metabolites of enzymatic hydrolysis of highland barley powder were studied in detail
Name | adduct | m/z | rt(min) | VIP | Fold change | Variation | p-value |
(-)-Epicatechin | [M-H]- | 289.07156 | 2.809 | 3.446483926 | 0.047124696 | ↓ | 2.85023E-15 |
Nystose | [M-H]- | 711.22223 | 0.673 | 1.884029667 | 0.018140886 | ↓ | 4.29346E-14 |
Epigallocatechin | [M-H]- | 305.0654 | 1.94 | 1.457363206 | 0.004744973 | ↓ | 8.19879E-14 |
(2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6 -[5-hydroxy-2-(4-hydroxyphenyl)-6-methoxy-4-oxochromen-7-yl]oxyoxane-2-carboxylic acid | [M-H]- | 475.08737 | 4.494 | 1.196902241 | 0.109614142 | ↓ | 9.06315E-14 |
Dimorphecolic acid | [M-H]- | 295.22916 | 9.915 | 3.1492803 | 0.296490224 | ↓ | 9.55879E-14 |
9-HOTrE | [M-H]1- | 293.21262 | 9.165 | 1.679152834 | 0.317792001 | ↓ | 1.38389E-13 |
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] octadeca-9,12-dienoate | [M-H]- | 476.2774 | 10.515 | 3.468110314 | 0.270945281 | ↓ | 2.98062E-13 |
Hydron;nonanedioate | [M-H]- | 187.09837 | 5.067 | 1.103199872 | 0.100934839 | ↓ | 5.91873E-13 |
L-Pyroglutamic acid | [M-H]- | 128.03435 | 0.688 | 1.121168248 | 0.027392905 | ↓ | 6.02342E-13 |
Lactose | [M-H]- | 387.11432 | 0.658 | 6.058193744 | 0.111504921 | ↓ | 1.14351E-12 |
Procyanidin B2 | [M-H]- | 577.13635 | 2.382 | 3.602385527 | 0.002536368 | ↓ | 1.59637E-12 |
Trehalose | [M-H]- | 341.112 | 0.659 | 5.456679882 | 0.206693496 | ↓ | 2.05188E-12 |
Bavachin | [M-H]- | 323.13562 | 2.726 | 1.481558198 | 0.000292826 | ↓ | 2.94275E-12 |
Xanthorhamnin | [M-H]- | 769.22083 | 4.773 | 1.176377243 | 0.054824501 | ↓ | 5.17346E-12 |
FA 18:1;3O | [M-H]- | 329.23199 | 7.285 | 1.434624998 | 0.288840431 | ↓ | 1.55831E-11 |
L-Malic acid | [M-H]- | 133.01324 | 0.657 | 2.73397094 | 0.00229625 | ↓ | 2.98909E-11 |
Fumaric acid (not validated) | [M-H]- | 115.00341 | 0.639 | 1.495327979 | 0.013087708 | ↓ | 5.81406E-11 |
Raffinose | [M-H]- | 503.16055 | 0.666 | 3.541632442 | 0.073348568 | ↓ | 7.26814E-11 |
Apigenin | [M-H]- | 269.04559 | 6.211 | 1.911242699 | 3.35774162 | ↑ | 7.36692E-11 |
4-Hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1H-benzo[f][2]benzofuran-3-one | [M-H]- | 377.08414 | 0.654 | 2.792969744 | 0.215352588 | ↓ | 2.64941E-10 |
Gluconic acid | [M-H]- | 195.05064 | 0.625 | 1.698743566 | 0.084579487 | ↓ | 5.8884E-10 |
Stachyose | [M-H]- | 665.21631 | 0.673 | 1.433406038 | 0.053727126 | ↓ | 1.40185E-09 |
Tubuloside A | [M-H]- | 827.27338 | 0.678 | 1.018637883 | 0.031227582 | ↓ | 2.29666E-09 |
Phosphatidylcholine lyso 16:0 | [M-CH3]- | 480.31055 | 10.788 | 1.302602501 | 0.439067711 | ↓ | 3.24154E-09 |
(Z)-5,8,11-Trihydroxyoctadec-9-enoic acid | [M-H]- | 329.23221 | 7.658 | 1.529075115 | 0.249575064 | ↓ | 4.05833E-09 |
(2Z)-4,6-Dihydroxy-2-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-1-benzofuran-3-one | [M-H]- | 329.06702 | 6.233 | 3.983452553 | 1.383372348 | ↑ | 1.75721E-08 |
FA 18:2;O | [M-H]- | 295.22684 | 11.867 | 1.202267104 | 0.649513406 | ↓ | 1.9305E-08 |
Luteolin | [M-H]- | 285.04068 | 5.799 | 1.9869953 | 0.701054733 | ↑ | 2.14058E-07 |
3-Phenoxybenzoic acid | [M-H]- | 213.05565 | 4.95 | 1.323728565 | 1.504013752 | ↑ | 4.11093E-07 |
FA 18:0;O | [M-H]- | 299.25613 | 11.156 | 1.124046492 | 0.202392854 | ↑ | 1.80656E-06 |
PG 36:4 | [M-H]- | 769.50232 | 12.499 | 1.121064744 | 0.766497762 | ↑ | 8.82294E-06 |
PE 36:3 | [M-H]- | 740.52411 | 12.734 | 1.643899895 | 0.666542597 | ↑ | 3.25296E-05 |
D-Glucose | [M-H]- | 179.05573 | 0.652 | 1.836605904 | 1.169281969 | ↑ | 3.45763E-05 |
Kaempferol 3,7-diglucoside | [M-H]- | 609.34161 | 7.477 | 2.991711928 | 1.165011072 | ↑ | 6.56922E-05 |
PI 34:2 | [M-H]- | 833.52142 | 12.985 | 1.477633663 | 0.393677199 | ↓ | 0.000606235 |
Linoleic acid | [M-H]- | 279.23108 | 12.372 | 1.526504634 | 0.928854244 | ↑ | 0.011912493 |
Flavone base + 4O, C-Hex-dHex | [M-H]- | 593.15295 | 5.352 | 1.333552772 | 0.086798914 | ↓ | 0.025719417 |
Maysin | [M-H]- | 575.14008 | 5.345 | 2.740124396 | 0.066813033 | ↓ | 0.029996321 |
Gingerol | [M-H]- | 293.17523 | 7.478 | 7.246968799 | 0.96249008 | ↑ | 0.031715141 |
As shown in Table 2, In cation detection mode, 34 differential metabolites were identified by matching against the database (VIP > 1.0, P < 0.05). Among them, 7 differential metabolites were related to the KEGG metabolic pathway, including organic nitrogen compounds (choline, alpha-Linolenoyl ethanolamide), organic oxygen compounds (sucrose), organic acids and their derivatives (N,N-Dimethylarginine, 4-Guanidinobutyric acid), Phenylpropanoids and polyketides ( Biochanin A 7-O-beta-d-glucoside-6 " -O-malonate ), nucleosides, nucleotides and analogues ( Cyclic AMP ) Among these metabolites, 12 metabolites were up-regulated and 22 were down-regulated. The up-regulated metabolites include isoprene lipids, peptide mimics, etc. The down-regulated metabolites include organic oxygen compounds, fatty acyl, etc.
Table 2
The positive detection mode (opls-da vip > 1, p value < 0.05), the differential metabolites of enzymatic hydrolysis of highland barley powder were studied in detail
Name | adduct | m/z | rt(min) | VIP | Fold change | Variation | p-value |
Phenylbutyrylglutamine | [M + H]+ | 293.1604 | 3.075 | 2.531248905 | 0.003903474 | ↓ | 3.92393E-17 |
Feruloyl lysine | [M + H]+ | 323.172 | 3.338 | 2.246101033 | 0.069069118 | ↓ | 9.23129E-17 |
2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | [M + H]+ | 268.10413 | 1.944 | 1.121847272 | 0.156354357 | ↓ | 6.50774E-16 |
beta-Maltose | [M + H]+ | 343.12317 | 0.662 | 1.460233039 | 0.046422054 | ↓ | 2.3069E-15 |
Betaine | [M + H]+ | 118.08568 | 0.643 | 5.64539765 | 0.061609564 | ↓ | 2.60796E-15 |
Feruloyl agmatine | [M + H]+ | 307.1767 | 3.742 | 1.384636512 | 0.078509009 | ↓ | 6.93505E-14 |
alpha-Linolenoyl ethanolamide | [M + H]+ | 322.27231 | 8.975 | 1.403782895 | 0.154790416 | ↓ | 1.24133E-13 |
Choline | [M]+ | 104.10628 | 0.662 | 2.924582075 | 0.345913074 | ↓ | 1.33574E-13 |
Maltotriose | [M + Na]+ | 527.15857 | 0.686 | 1.769157317 | 0.346595626 | ↓ | 2.3205E-13 |
Steviol | [M + H]+ | 319.22534 | 9.57 | 1.047087644 | 0.567461397 | ↓ | 1.1252E-12 |
N,N-Dimethylarginine | [M + H]+ | 203.15067 | 0.748 | 1.043853234 | 0.038495255 | ↓ | 1.20307E-12 |
Glyceryl monooleate | [M + H]+ | 357.29947 | 11.289 | 2.008084293 | 0.464566677 | ↓ | 2.67875E-12 |
1-O-linoleoyl-3-O-beta-D-galactopyranosyl-syn-glycerol | [M + NH4]+ | 534.36261 | 10.592 | 1.254295407 | 0.10749055 | ↓ | 2.99043E-12 |
5-dodecyl-4-hydroxy-4-methylcyclopent-2-en-1-one | [M + H-H2O]+ | 263.23468 | 12.4 | 1.830536702 | 7.572333708 | ↑ | 3.13985E-12 |
[5-(2-Hydroxy-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl)-3-methylpentyl] acetate | [M-H2O + H]+ | 335.29221 | 12.091 | 1.420276012 | 38.61167874 | ↑ | 9.23025E-12 |
n-Oleoylethanolamine | [M + H]+ | 326.30615 | 11.081 | 1.452149851 | 0.164196386 | ↓ | 1.29795E-11 |
Surfactin | [M + H]+ | 1036.68787 | 11.41 | 1.001254911 | 57.59420717 | ↑ | 1.01505E-10 |
5-(5-Methoxycarbonyl-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl)-3-methylpentanoic acid | [M + H]+ | 351.25278 | 9.181 | 1.247353424 | 0.429408817 | ↓ | 3.17406E-10 |
(2-Hydroxy-3-octadeca-6,9,12-trienoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate | [M + H]+ | 518.32227 | 10.104 | 2.274145447 | 0.463054007 | ↓ | 4.88507E-10 |
2-(((R)-2,3-Dihydroxypropyl)phosphoryloxy)-N,N,N-trimethylethanaminium | [M]+ | 258.11105 | 0.619 | 1.881624012 | 0.080824773 | ↓ | 1.19845E-09 |
Sucrose | [M + Na]+ | 365.10562 | 0.661 | 4.753818957 | 6.65279446 | ↑ | 2.32119E-08 |
1-Hexadecanoyl-sn-glycero-3-phosphoethanolamine | [M + H]+ | 454.2901 | 10.802 | 1.217417143 | 0.326799432 | ↓ | 5.46184E-08 |
(6beta,22E)-6-Hydroxystigmasta-4,22-dien-3-one | [M + H]+ | 427.35568 | 12.39 | 1.414627471 | 1.329728779 | ↑ | 9.04358E-08 |
beta-Gentiobiose | [M + NH4]+ | 360.15021 | 0.656 | 1.13694152 | 0.698248743 | ↓ | 1.59354E-07 |
4-Guanidinobutyric acid | [M + H]+ | 146.09116 | 0.705 | 1.008797731 | 0.031308841 | ↓ | 5.59524E-07 |
Avocadene 4-acetate | [M + Na]+ | 351.25171 | 12.896 | 1.319152241 | 1.191310088 | ↑ | 1.98448E-05 |
N-Desmethyltramadol | [M + H]+ | 250.17816 | 6.972 | 1.190142318 | 1.353080555 | ↑ | 2.22753E-05 |
Fibleucin | [M + H]+ | 357.18555 | 5.475 | 1.493693437 | 0.060528217 | ↓ | 0.000537587 |
Biochanin A 7-O-beta-d-glucoside-6''-O-malonate | [M + H]+ | 533.4165 | 12.83 | 1.087377858 | 1.174500524 | ↑ | 0.000634626 |
Cyclic AMP | [M + H]+ | 330.3374 | 10.291 | 1.200940559 | 0.607386376 | ↓ | 0.001095802 |
alpha-Spinasterol | [M + H-H2O]+ | 395.36487 | 12.677 | 1.210028951 | 1.339489288 | ↑ | 0.004537202 |
2,4-Dihydroxyheptadecyl acetate | [M-H2O + H]+ | 313.27072 | 13.825 | 1.412480674 | 1.489043385 | ↑ | 0.006251986 |
6-{9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,8H,9H,9bH,10H,11H-cyclopenta[a]phenanthren-1-yl}-3-ethyl-2-methylheptane | [M + H]+ | 397.3815 | 14.043 | 1.235515418 | 1.256297606 | ↑ | 0.046051593 |
L-Glutathione (oxidized form) | [M + H]+ | 613.47644 | 13.401 | 1.062153722 | 1.112520503 | ↑ | 0.047324414 |
In order to more intuitively show the relationship between samples and the expression differences of metabolites between different samples, a heat map analysis was performed on the expression of significantly different metabolites enriched in pathways in two modes of anion and cation (Fig. 3). Each row in the figure represents a differential metabolite, each column represents a sample, and each of the control group and the PG group has 3 samples. Blue is the low-expressing substance, and red is the high-expressing metabolite. From blue to red, the expression level of the substance is from low to high. The PG group and the Contral group were clearly separated, indicating that there were significant differences between the two groups, and the screened metabolites with significant differences could be used as markers to distinguish the two groups.
Functional annotation of differential metabolites and their enrichment analysis and kegg metabolic pathway analysis
Comprehensive analysis of differential metabolites in both cation and anion modes to ensure comprehensiveness and improve confidence. Functional annotation of differential metabolites revealed that 138 metabolic pathways were integrated, covering 20 metabolites. Among them, metabolic pathways mainly include Flavonoid biosynthesis, GIucagon signaling pathway, Taste transduction, and ABC transporters (Fig. 4). Differential abundance analysis (DA) showed that at least 61 metabolites out of 57 metabolic pathways were captured (P < 0.05), of which 56 metabolic pathways were high (<-0.5 DA score, blue) and 1 metabolic pathways were low (> 0.5 da score, red) (Fig. 5). The up-regulated metabolic pathways mainly include Isoflavonoid biosynthesis. Down-regulated metabolic pathways mainly include Glucagon signaling pathway, Cholinergic synapse, etc.